NCT00003601 2023-06-18
Tretinoin With or Without Fenretinide in Treating Patients With Dysplastic Nevus Syndrome
Eastern Cooperative Oncology Group
Phase 2 Completed
Clinical Trials
13 trialsNCT02495415 2019-07-23
Trial of Intravenous Fenretinide Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas
CerRx, Inc.
Phase 2 Unknown
NCT00006471 2018-11-01
Fenretinide in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00006080 2018-06-27
Fenretinide in Treating Patients With Recurrent Malignant Glioma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT00080899 2015-03-06
Fenretinide in Treating Patients With Biochemically Recurrent Hormone-Naïve Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00053326 2013-10-08
Fenretinide in Treating Children With Recurrent or Resistant Neuroblastoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00077402 2013-05-15
Fenretinide In Treating Patients With Advanced or Metastatic Hormone-Refractory Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00004161 2013-04-12
Fenretinide in Treating Patients With Leukoplakia of the Mouth
University of Alabama at Birmingham
Phase 2 Completed
NCT00011973 2013-04-05
Chemotherapy in Treating Patients With Advanced Kidney Cancer
Barbara Ann Karmanos Cancer Institute
Phase 2 Completed
NCT00026091 2013-03-25
Fenretinide in Treating Patients With Recurrent or Metastatic Ovarian Epithelial or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00009971 2013-02-11
Fenretinide in Treating Patients With Recurrent Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00003099 2012-07-30
Chemoprevention Therapy Plus Surgery in Treating Women With Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00003223 2012-07-24
SWOG-9507, Fenretinide in Treating Patients With Neoplasia of the Mouth
SWOG Cancer Research Network
Phase 2 Terminated